AZT ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
94	Primary sclerosing cholangitis	1
265	Lipodystrophy	2
325	Hereditary autoinflammatory syndrome	1

94. Primary sclerosing cholangitis

Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs051180120	01/04/2012	13/03/2019	Examination of the mizoribine and azathioprine combination immunosuppressive therapy in primary sclerosing cholangitis	Examination of the immunosuppressive drug combination therapy in primary sclerosing cholangitisStudy of the mizoribine and azathioprine combination immunosuppressive therapy - Examination of the immunosuppressive drug combination therapy in primary sclerosing cholangitis	Primary sclerosing cholangitis; PSC;K830	1 MZR Daily intake of mizoribine once before breakfast. Dose adjustment is done to achieve a blood concentration level over 3.0 microg/ml at 3 hour after meal. 2)AZT Daily intake of azathioprine once after breakfast and once after dinner. Starting dose is 0.5-1.0mg/kg daily (max 2.0mg) , is increased according to the condition of patients. Dose is adjusted to achieve WBC 3000-5000/m3, neutrophils 2000-3500/m3(the dose of 6MP is appotoimatery half of azathioprine). Continue the dosage during a study period.	Tajiri Hitoshi	NULL	Complete	>= 3age old	<= 18age old	Both	10	Phase 2	Japan

265. Lipodystrophy

Clinical trials : 116 / Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-004021-26-GB (EUCTR)	06/10/2005	05/09/2005	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study	Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. - Mitochondrial DNA Study	HIV	Trade Name: SUSTIVA Product Name: Efavirenz Trade Name: COMBIVIR Product Name: AZT/3TC Trade Name: TRUVADA Product Name: emtricitabine/tenofovir	University Hospital Birmingham	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): yes	United Kingdom
2	NCT00192621 (ClinicalTrials.gov)	November 2004	12/9/2005	Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects	A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism	HIV Infections;Dyslipidemias;Glucose Metabolism Disorders;Metabolic Diseases;Lipodystrophy;Cardiovascular Disease	Drug: Combivir (zidovudine [AZT] / lamivudine [3TC]);Drug: Kaletra (lopinavir [LPVr])	Kirby Institute	St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;Prince of Wales Hospital, Sydney	Completed	18 Years	N/A	Both	50	Phase 4	Australia

325. Hereditary autoinflammatory syndrome

Clinical trials : 7 / Drugs : 16 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04731103 (ClinicalTrials.gov)	February 2022	14/7/2020	Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology	Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology	Aicardi-Goutières Syndrome	Drug: Abacavir (ABC);Drug: Lamivudine (3TC);Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)	University of Edinburgh	NHS Lothian;Medical Research Council	Not yet recruiting	3 Months	15 Years	All	24	Phase 2	United Kingdom